5/30
04:02 pm
crvs
Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
Low
Report
Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
5/20
08:30 am
crvs
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Corvus Pharmaceuticals, Inc. (CRVS) and Encourages Investors to Contact the Firm
Low
Report
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Corvus Pharmaceuticals, Inc. (CRVS) and Encourages Investors to Contact the Firm
5/10
07:25 am
crvs
Insider Spends US$1m Buying More Shares In Corvus Pharmaceuticals [Yahoo! Finance]
Low
Report
Insider Spends US$1m Buying More Shares In Corvus Pharmaceuticals [Yahoo! Finance]
5/7
11:21 am
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/7
08:17 am
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $7.00 to $8.00. They now have an "outperform" rating on the stock.
High
Report
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $7.00 to $8.00. They now have an "outperform" rating on the stock.
5/6
04:10 pm
crvs
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]
High
Report
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]
5/6
04:01 pm
crvs
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
High
Report
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
5/2
04:13 pm
crvs
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024 [Yahoo! Finance]
High
Report
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024 [Yahoo! Finance]
5/2
04:02 pm
crvs
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
High
Report
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
5/2
08:43 am
crvs
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering [Yahoo! Finance]
Medium
Report
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering [Yahoo! Finance]
5/2
08:30 am
crvs
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
High
Report
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
4/9
04:04 pm
crvs
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis [Yahoo! Finance]
High
Report
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis [Yahoo! Finance]
4/9
04:01 pm
crvs
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Medium
Report
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
4/1
12:17 pm
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
3/27
02:11 pm
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "neutral" rating re-affirmed by analysts at Mizuho. They now have a $3.50 price target on the stock.
Low
Report
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "neutral" rating re-affirmed by analysts at Mizuho. They now have a $3.50 price target on the stock.
3/21
10:01 am
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/20
08:08 am
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $8.00 to $7.00. They now have an "outperform" rating on the stock.
Low
Report
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $8.00 to $7.00. They now have an "outperform" rating on the stock.
3/19
04:19 pm
crvs
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
High
Report
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
3/19
04:02 pm
crvs
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Medium
Report
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results